Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711478 | 0.82 | PLAAT3 (0.59) | SMN1; SMN2KDM4ENPC1L3MBTL1ALDH1A1 | |
| SCHEMBL15682681 | 0.81 | TGM2 (0.54) | KDM4EL3MBTL1LMNAALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL3467436 | 0.81 | SMN1; SMN2 (0.66) | TP53SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL17235945 | 0.81 | CYP2C9 (0.65) | TP53SMN1; SMN2KDM4ENPC1L3MBTL1 | |
| SCHEMBL15682670 | 0.81 | LMNA (0.56) | TP53SMN1; SMN2NPC1L3MBTL1LMNA | |
| SCHEMBL881512 | 0.81 | KMT2A (0.61) | SMN1; SMN2KDM4ENPC1L3MBTL1LMNA | |
| SCHEMBL14670000 | 0.80 | ALDH1A1 (0.57) | TP53SMN1; SMN2KDM4ENPC1L3MBTL1 | |
| SCHEMBL5528831 | 0.79 | CYP2C9 (0.66) | TP53SMN1; SMN2KDM4ENPC1LMNA | |
| SCHEMBL2730689 | 0.78 | SMN1; SMN2 (0.85) | TP53SMN1; SMN2NPC1LMNAALDH1A1 | |
| SCHEMBL3662909 | 0.78 | SMN1; SMN2 (0.71) | TP53SMN1; SMN2KDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348365-A1 | COMPOUNDS FOR TREATING INFECTIONS | ARTS & CIÈNCIES EUROPA (AD) | 2023-11-02 | — | — | US | disclosed |
| EP-2914575-B1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | UNIV MICHIGAN REGENTS (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | EASTERN MICHIGAN UNIVERSITY | 2017-10-12 | — | — | US | disclosed |
| US-9718760-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718760-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014070983-A1 | PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-08 | — | — | WO | disclosed |
| US-5051517-A | Reacting a chloroformidine hydrochloride with an oxamohydrazide, forming bonds between carbon and nitrogen and cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348365-A1 | COMPOUNDS FOR TREATING INFECTIONS | DPM1, TREH, MPO | TP53 2353/4885SMN1; SMN2 4715/4885KDM4E 2557/4885 |
| US-20170291893-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | TP53 4391/4885SMN1; SMN2 3209/4885KDM4E 4091/4885 |
| US-20150315178-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF | SERPINE1, PLAT, SERPINC1 | TP53 4391/4885SMN1; SMN2 3209/4885KDM4E 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.